Definium Therapeutics, Inc. (DFTX)
Data as of , from SEC Form 4 filings.
See up to 3 months of DFTX. The 7-day demo opens the 1M and 3M ranges and puts DFTX on your watchlist.
Start 7-day demoLatest DFTX insider trades
About Definium Therapeutics, Inc. (DFTX)
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
- NEW YORK, NY
- 106
- 2020
- XNAS
DFTX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 6 | 81,951 | $3.02M |
| Grant or award | 11 | 2,027,500 | |
| Option exercise | 4 | 5,430 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
DFTX insider transactions (Form 4)
3555 Form 4 filings on record, the earliest from Dec 5, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Daniel Karlin - Officer | Open-market sale | Common Shares | 10,853 | $36.57 footnote F2 | $397K | |
| ||||||
| Robert Barrow - Officer | Open-market sale | Common Shares | 31,550 | $36.57 footnote F2 | $1.15M | |
| ||||||
| Matthew T. Wiley - Officer | Open-market sale | Common Shares | 3,097 | $36.57 footnote F2 | $113K | |
| ||||||
 Mark Sullivan - Officer | Open-market sale | Common Shares | 14,051 | $36.57 footnote F2 | $514K | |
| ||||||
| Brandi Roberts - Officer | Open-market sale | Common Shares | 3,377 | $36.57 footnote F2 | $123K | |
| ||||||
 Carol A. Vallone - Director | Option exercise | Common Shares | 1,086 | $35.52 | $39K | |
| Carol A. Vallone - Director | Option exercise | Stock Option (Right to Buy) | 1,086 | $0.00 | - | |
| Andreas Krebs - Director | Option exercise | Common Shares | 1,629 | $35.52 | $58K | |
| Andreas Krebs - Director | Option exercise | Stock Option (Right to Buy) | 1,629 | $0.00 | - | |
| Daniel Karlin - Officer | Grant or award | Common Shares | 200,000 footnote F1 | $0.00 | - | |
| ||||||
| Matthew T. Wiley - Officer | Grant or award | Common Shares | 125,000 footnote F1 | $0.00 | - | |
| ||||||
| Mark Sullivan - Officer | Grant or award | Common Shares | 125,000 footnote F1 | $0.00 | - | |
| ||||||
| Brandi Roberts - Officer | Grant or award | Common Shares | 125,000 footnote F1 | $0.00 | - | |
| ||||||
| Robert Barrow - Officer | Grant or award | Common Shares | 750,000 footnote F1 | $0.00 | - | |
| ||||||
| Robert Barrow - Officer | Grant or award | Common Shares | 40,000 footnote F1 | $0.00 | - | |
| Robert Barrow - Officer | Open-market sale | Common Shares | 19,023 | $37.94 footnote F4 | $722K | |
| ||||||
| Robert Barrow - Officer | Grant or award | Common Shares | 375,000 footnote F1 | $0.00 | - | |
| ||||||
| Daniel Karlin - Officer | Grant or award | Common Shares | 100,000 footnote F1 | $0.00 | - | |
| ||||||
| Mark Sullivan - Officer | Grant or award | Common Shares | 62,500 footnote F1 | $0.00 | - | |
| ||||||
| Matthew T. Wiley - Officer | Grant or award | Common Shares | 62,500 footnote F1 | $0.00 | - | |
| ||||||
| Brandi Roberts - Officer | Grant or award | Common Shares | 62,500 footnote F1 | $0.00 | - | |
| ||||||
| Mark Sullivan - Officer | Open-market sale | Common Shares | 13,008 | $45.03 | $586K | |
| Brandi Roberts - Officer | Open-market sale | Common Shares | 3,013 | $45.03 | $136K | |
| Robert Barrow - Officer | Open-market sale | Common Shares | 29,208 | $45.03 | $1.32M | |
| Daniel Karlin - Officer | Open-market sale | Common Shares | 10,035 | $45.03 | $452K | |
| Matthew T. Wiley - Officer | Open-market sale | Common Shares | 2,867 | $45.03 | $129K | |
| Matthew T. Wiley - Officer | Grant or award | Common Shares | 62,500 footnote F1 | $0.00 | - | |
| ||||||
| Robert Barrow - Officer | Grant or award | Common Shares | 375,000 footnote F1 | $0.00 | - | |
| ||||||
| Mark Sullivan - Officer | Grant or award | Common Shares | 62,500 footnote F1 | $0.00 | - | |
| ||||||
| Brandi Roberts - Officer | Grant or award | Common Shares | 62,500 footnote F1 | $0.00 | - | |
| ||||||
| Daniel Karlin - Officer | Grant or award | Common Shares | 100,000 footnote F1 | $0.00 | - | |
| ||||||
 Roger Crystal | Grant or award | Common Shares | 4,666 footnote F1 | $0.00 | - | |
| Roger Crystal | Grant or award | Stock Option (Right to Buy) | 19,188 | $0.00 | - | |
| ||||||
| David W. Gryska | Grant or award | Common Shares | 4,666 footnote F1 | $0.00 | - | |
| David W. Gryska | Grant or award | Stock Option (Right to Buy) | 19,188 | $0.00 | - | |
| ||||||
Item 7.01, 8.01, 9.01
Item 8.01, 9.01
Item 7.01, 8.01, 9.01
Item 2.02, 9.01
Recent DFTX Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| MARK SULLIVAN | Officer | 14,051 | $516K | View on EDGAR | |
| BRANDI ROBERTS | Officer | 3,377 |
DFTX insider trading FAQ
What is the latest insider trade for DFTX?
Definium Therapeutics, Inc. (DFTX) had 18 insider filings in the last 90 days, with the most recent on 2026-09-30. The full record for DFTX runs to 55 Form 4 filings, the earliest from 2024-12-05. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying DFTX stock?
No insider purchases of DFTX were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling DFTX stock?
6 insider sales of DFTX were filed in the last 90 days, totaling $3.02M.
Where can I see DFTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects DFTX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Daniel Karlin view on EDGAR
- - Robert Barrow view on EDGAR
- - Matthew T. Wiley view on EDGAR
- - Mark Sullivan view on EDGAR
- - Brandi Roberts view on EDGAR
- - Carol A. Vallone view on EDGAR
- - Andreas Krebs view on EDGAR
- - Daniel Karlin view on EDGAR
- - Matthew T. Wiley view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where DFTX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow DFTX with a 7-day demo
- DFTX on your watchlist
- Every DFTX Form 4 filing on record
- Up to 3 months of DFTX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
